Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

HIVR4P Home

Funding for this conference was made possible in part by 1R13AI136762-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices or organizations imply endorsement by the U.S. Government.

The conference was supported by Gilead, which provided funding. Gilead has had no input into the content of the materials used at this meeting/conference.

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 9 of 9
Satellite Session: Planning for Success: Next Steps for Dapivirine Ring
Introduction and Objectives for the Session
Maureen Luba
AVAC, Kenya
Research and Modeling Update: Choosing Choice: Women's Voices
Cleopatra Makura
SAYWHAT, Zimbabwe
Shakirah Namwanje
Because I am a Girl Campaign, Uganda
Research and Modeling Update: Research & Regulatory Update
Zeda Rosenberg
IPM
Research and Modeling Update: Modeling Update: How do those data translate into potential impact?
Katharine Kripke
Avenir/OPTIONS
Research and Modeling Update: Q&A
Maureen Luba
AVAC, Kenya
Cleopatra Makura
SAYWHAT, Zimbabwe
Shakirah Namwanje
Because I am a Girl Campaign, Uganda
Zeda Rosenberg
IPM
Katharine Kripke
Avenir/OPTIONS
What are the opportunities (and challenges) for introducing the ring?: Questions for Donors, Policy Makers, and Advocates
Wanjiru Mukoma
LVCT Health, Kenya
Benny Kottiri
USAID
Taurai Bhatasara
MOHCC-Zimbabwe
Michelle Rodolph
WHO
Lillian Mworeko
International Community of Women Living with HIV/AIDS
Planning for Introduction: Country Analyses: What questions remain about the ring and where can we answer them?
Imelda Mahaka
Pangaea Zimbabwe AIDS Trust (PZAT)/OPTIONS)
Planning for Introduction: Demonstrating for Impact: How can we most effectively answer the remaining questions?
Jared Baeten
University of Washington, United States
Planning for Introduction: Preparing for Introduction: What do we need to understand about the ring market?
Nadia Sutton
J&J Global Public Health
Planning for Introduction: How can we efficiently move from research to rollout?
Elizabeth Gardiner
AVAC/OPTIONS
Planning for Introduction: Q&A
Wanjiru Mukoma
LVCT Health, Kenya
Imelda Mahaka
Pangaea Zimbabwe AIDS Trust (PZAT)/OPTIONS)
Jared Baeten
University of Washington, United States
Nadia Sutton
J&J Global Public Health
Elizabeth Gardiner
AVAC/OPTIONS
Wrap up
Maureen Luba
AVAC, Kenya
Wanjiru Mukoma
LVCT Health, Kenya
from HIV Research for Prevention 2018 on 21 October 2018 14:00-17:00
Satellite Session: State of the Art of HIV bNAbs for Prevention of HIV Infection
Introduction
Mike Cohen
HIV Prevention Trials Network
Larry Corey
HIV Prevention Trials Network
Review of bNAbs in Clinical Development
Rick Koup
Vaccine Research Center/NIAID, NIH, United States
Where are we in AMP Trial?
Sri Edupuganti
Emory Vaccine Research Center, United States
Developing Neutralization as a Surrogate Marker of Efficacy
David Montefiori
Duke Laboratory for AIDS Vaccine Research and Development, United States
Modelling Coverage with Combination Monoclonals: The 2 vs. 3 Issue
Bette Korber
Los Alamos National Laboratory, United States
Altering the PK: LS mutation PKs
Julie Ledgerwood
Vaccine Research Center/NIAID, NIH, United States
The Role of Fc Function in Efficacy
Dan Barouch
Harvard Center for Virology and Vaccine Research, United States
from HIV Research for Prevention 2018 on 21 October 2018 16:00-18:00
Satellite Session: A Treasure Trove of Clinical Specimens and Data: Mining Research Opportunities with the HIV Vaccine Trials Network (HVTN)
Welcome & introduction to the HVTN
James Kublin
HIV Vaccine Trials Network, United States
Overview of HVTN specimens & data
Jessica Andriesen
HIV Vaccine Trials Network, United States
HVTN: Collaborate with us!
Ashley Clayton
HIV Vaccine Trials Network, United States
Monitoring the development of broadly neutralizing HIV-1 antibodies in an HVTN 503/Phambili participant
Andrew McGuire
Fred Hutchinson Cancer Research Center, United States
HIV Env-specific peripheral blood plasmablasts and clonal persistence in bone marrow plasma cells following vaccination in humans
James Kobie
University of Rochester, United States
Detection of HIV-specific T-cell lytic granule loading, exocytosis and cytotox-ic capacity in recipients of HIV-1 vaccines
Stephen Migueles
NIAID, NIH, United States
HLA-I associated adaptation to HIV Ad5 vaccines dampens the CD8 T-cell re-sponse in recipients
Sushma Boppana
University of Alabama at Birmingham, United States
Antigen-specific NK cells induced by HIV and HIV vaccines
R. Keith Reeves
Harvard Medical School/Beth Israel Deaconess Medical Center, United States
Overview of HVTN Social & Behavioral Data and Analyses
Michele Andrasik
HIV Vaccine Trials Network, United States
Final remarks and closing
James Kublin
HIV Vaccine Trials Network, United States
from HIV Research for Prevention 2018 on 22 October 2018 08:30-11:30
Satellite Session: Catalyzing Translational Research to Advance HIV Vaccine and Immune-based Cure Research in Africa
Satellite co-chair
Daniel Ochiel
IAVI, Kenya
Satellite co-chair
Thumbi Ndungu
UKZN, South Africa
Satellite opening remarks
Margaret McCluskey
USAID, United States
Overview of research capacity building opportunities in Africa
Anatoli Kamali
IAVI, Kenya
Replicative capacity of transmitted gag drives HIV pathogenesis
Gladys Macharia
Imperial College
Pol replication capacity impacts disease progression in HIV subtype C infection: implications for vaccine design
Doty Achieng
UKZN, South Africa
Near full-length genome characterization of HIV-1 subtypes among drug users in Kenya
Thando Zulu
UKZN, South Africa
Rustenburg Clinical Research Site (RCRS) HSP Mapping IIR
William Brumskine
Aurum Institute, South Africa
Effectiveness of a counselling intervention to increase linkage to care after home-based HIV testing: a cluster-randomised trial in Uganda
Eugene Ruzagira
MRC/UVRI and LSHTM Uganda Research Unit, Uganda
Clinical Research experience at Projet San Francisco: 15 years of IAVI capacity building program in Rwanda
Julien Nyombayire
PSF/Rwanda-Zambia HIV Research Group, Rwanda
Building Sustainable Research Capacity: Achieving the Ripple Effect
Gaudensia Mutua
KAVI-ICR, University of Nairobi, Kenya
Epidemiology of alcohol misuse, illicit drug use & their association with HIV among young people aged 15-24 years in fishing communities in Uganda
Monica Kuteesa
MRC/UVRI and LSHTM Uganda Research Unit, Uganda
Panel Discussion: Moderator
Eunice Nduati
KEMRI Kilifi, Kenya
Panelist
Julien Nyombayire
PSF/Rwanda-Zambia HIV Research Group, Rwanda
Panelist
Gladys Macharia
Imperial College
Panelist
Dennis Chopera
SANTHE, South Africa
Panelist
Doty Achieng
UKZN, South Africa
Panelist
Monica Kuteesa
MRC/UVRI and LSHTM Uganda Research Unit, Uganda
Panelist
Eugene Ruzagira
MRC/UVRI and LSHTM Uganda Research Unit, Uganda
Panelist
William Brumskine
Aurum Institute, South Africa
IAVI DataSpace
Roger Tatoud
IAVI, HIL
Satellite closing remarks
Margaret McCluskey
USAID, United States
from HIV Research for Prevention 2018 on 22 October 2018 08:30-11:30
Satellite Session: Current State of Play: PrEP Implementation Update and Challenges
Welcome Remarks
Wafaa El-Sadr
ICAP at Columbia University, United States
Welcome Remarks
Emily Donaldson
AVAC, United States
Global Update: State of Oral PrEP Implementation and Scale-up
Michelle Rodolph
WHO, Switzerland
PrEP Implementation – Key Issues and Controversies: PrEP for Adolescent Girls and Young Women
Nelly Mugo
KEMRI, Kenya
PrEP Implementation – Key Issues and Controversies: PrEP in Women, Adherence vs. PK
Mike Cohen
UNC – Chapel Hill, United States
PrEP Implementation – Key Issues and Controversies: PrEP Persistence
Susan Buchbinder
UCSF, United States
PrEP Implementation – Key Issues and Controversies: Demedicalizing PrEP
Sheena McCormack
MRC, United Kingdom
PrEP Implementation – Key Issues and Controversies: Q&A
Wafaa El-Sadr
ICAP at Columbia University, United States
Nelly Mugo
KEMRI, Kenya
Mike Cohen
UNC – Chapel Hill, United States
Susan Buchbinder
UCSF, United States
Sheena McCormack
MRC, United Kingdom
Lessons Learned in Implementing & Scaling-up oral PrEP: Lessons from South Africa
Hasina Sudebar
National Department of Health, South Africa
Lessons Learned in Implementing & Scaling-up oral PrEP: Lessons from Kenya
Daniel Were
Jhpiego Kenya, Kenya
Lessons Learned in Implementing & Scaling-up oral PrEP: Lessons from Brazil
Beatriz Grinszteijn
INI, Brazil
Lessons Learned in Implementing & Scaling-up oral PrEP: Lessons from the United States
John Brooks
US CDC, United States
Lessons Learned in Implementing & Scaling-up oral PrEP: Lessons from Ukraine
Olga Denisiuk
Alliance for Public Health, Ukraine
Lessons Learned in Implementing & Scaling-up oral PrEP: Q&A
Emily Donaldson
AVAC, United States
Hasina Sudebar
National Department of Health, South Africa
Daniel Were
Jhpiego Kenya, Kenya
Beatriz Grinszteijn
INI, Brazil
John Brooks
US CDC, United States
Olga Denisiuk
Alliance for Public Health, Ukraine
Looking Ahead: Next Generation of PrEP
Nyaradzo Mgodi
UZ-UCSF Collaborative Research Programme
Closing Remarks
Wafaa El-Sadr
ICAP at Columbia University, United States
Closing Remarks
Emily Donaldson
AVAC, United States
from HIV Research for Prevention 2018 on 22 October 2018 08:30-11:30
Satellite Session: Immunological Mechanisms of Inducing HIV Immunity in Infants
Opening Remarks: Immune Landscape and HIV Vaccination
Anjali Singh
National Institutes of Health, United States
Opening Remarks: Early Life Immunization Strategies against HIV Acquisition
Mary Marovich
NIH/NIAID/Division of AIDS, United States
Elimination of HIV by Starting at the Beginning: Early Life HIV Immunization
Sallie Permar
Duke University School of Medicine, United States
Development and Maternal Determinants of Infant Immunity
Arnaud Marchant
Universite Libre de Bruxelles, Belgium
Precision Vaccine Approaches to Inform Development of Infant HIV Immunization
Ofer Levy
Boston Children's Hospital, United States
Antibodies Responses to HIV Infection and Vaccination in Adults and in Infants
Genevieve Fouda
Duke University School of Medicine, United States
Adaptive Immunity to HIV in Early Life - Learning from Infected Children
Maximilian Muenchhof
Max von Pettenkofer-Institut, Germany
Broadly Neutralizing Antibodies in HIV-Infected Children
Penny Moore
National Inst. for Communicable Diseases, RSA
Rationale Choice of Adjuvants for Pediatric HIV-1 Vaccines
Kristina De Paris
University of North Carolina, United States
Discussion Forum: Immune Ontogeny And Protective Hiv Immunity
Co-Moderator
Arnaud Marchant
Universite Libre de Bruxelles, Belgium
Co-Moderator
Ofer Levy
Boston Children's Hospital, United States
Panelist
Genevieve Fouda
Duke University School of Medicine, United States
Panelist
Maximilian Muenchhof
Max von Pettenkofer-Institut, Germany
Panelist
Penny Moore
National Inst. for Communicable Diseases, RSA
Panelist
Kristina De Paris
University of North Carolina, United States
Panelist
Georgia Tomaras
Duke University, United States
Panelist
M. Anthony Moody
Duke University, United States
Panelist
Wilton Williams
Duke University, United States
Panelist
Glenda Gray
University of the Witwatersrand, South Africa
Early Life HIV Vaccination Trials - Possibilities and Challenges
Mary Marovich
NIH/NIAID/Division of AIDS, United States
Vaccine Candidates and Hypotheses for Testing in Children
Barton Haynes
Duke University, United States
Neutralizing Monoclonal Antibodies in the Setting of Mother to Child Transmission
Richard Koup
National Institutes of Health, United States
Germline Targeting Immunization Strategies to Elicit Diverse Broadly Neutralizing Antibody Responses
Leonidas Stamatatos
Fred Hutch, United States
Immunogenicity of Native Trimeric HIV Envelope SOSIP Protein in Neonates and Adults
Rama Rao Amara
Emory University, United States
Germline Targeting HIV-1 Vaccines based on Native-like Envelope Trimers
Rogier Sanders
Weill Cornell Medical College, United States
Discussion Forum: Immune Obstacles And Hiv Vaccine Development
Co-Moderator
Mary Marovich
NIH/NIAID/Division of AIDS, United States
Co-Moderator
Barton Haynes
Duke University, United States
Panelist
Richard Koup
National Institutes of Health, United States
Panelist
Leonidas Stamatatos
Fred Hutch, United States
Panelist
Rama Rao Amara
Emory University, United States
Panelist
Rogier Sanders
Weill Cornell Medical College, United States
Panelist
Nina Russell,
Bill & Melinda Gates Foundation, United States
Panelist
Richard Wyatt
The Scripps Research Institute, United States
Panelist
Andrea Hulse
Food and Drug Administration, United States
Panelist
Thomas Hope
Northwestern University, United States
Panelist
Stuart Shapiro
National Institutes of Health, United States
from HIV Research for Prevention 2018 on 22 October 2018 08:30-11:30
Satellite Session: Fc-Mediated Antibody Functions Impacting HIV Prevention
Welcome and Opening Remarks
Mary Marovich
NIH/NIAID/Division of AIDS, United States
Higher Antibody Fc Effector Functions Significantly Impact HIV-1 Infection Risk in a Human Efficacy Trial
Georgia Tomaras
Duke University, United States
Epitopes For C1/C2 ADCC Antibodies Induced in HIV Infection and in Response to the RV144 and RV305 Vaccine Trials
Marzena Pazgier
Uniformed Services University of the Health Sciences, United States
Impact of HIV-1 Env Conformation on ADCC
Andrés Finzi
University of Montreal, Canada
Knowns and Unknowns: Antibody Fc-Mediated Anti-Viral Activity in Passive and Active Immunization
Ann Hessell
Oregon Health & Science University, United States
Role of Non-Neutralizing Effector Mechanisms in Sterilizing Immunity Conferred by Passive Immunization in NHPs
Klaus Überla
University Hospital Erlangen, Germany
The Link Between Fc Effector Function and Neutralization
Simone Richardson
NICD, South Africa
The immunomodulatory role of serum IgA upon Fc effector functions
Amy Chung
Doherty Institute, Australia
Time-dependent susceptibility of HIV-1-infected cells to ADCC
Wen Shi Lee
University of Melbourne, Australia
Contribution of Fc-Mediated Antibody Activities to HIV Control
Jéromine Klingler
INSERM, France
High Rate of anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy Volunteers
Frank Msafiri
Muhimbili Univ. of Health and Allied Sciences/Karolinska Inst., Tanzania/Sweden
Circulating levels of HIV-1-specific IgG differentially affect antibody-dependent cellular cytotoxic and phagocytic responses in HIV-1 infected individuals
Ntando Phaahla
NICD, South Africa
Good things come in threes: mAb combinations for killing infected cells
Marina Tuyishime
Duke University, United States
Panel Discussion: Co-Chair
Christiane Moog
INSERM, Univeristy of Strasbourg, France
Panel Discussion: Co-Chair
Stephen Kent
Doherty Institute, Australia
from HIV Research for Prevention 2018 on 22 October 2018 12:00-15:00
Satellite Session: Love, Power, and PrEP: Addressing relationship dynamics and intimate partner
Love, Power and PrEP: What we know, what we need to know
Sinead Delany-Moretlwe
Wits Reproductive Health and HIV Institute (Wits RHI), South Africa
Social influences for oral PrEP acceptance among adolescent girls & young women, male partners, & female sex workers in Tanzania and Ghana
Nanlesta Pilgrim
Population Council, United States
Tu'Washindi na PrEP: Understanding how relationship dynamics and IPV influence PrEP use among young women in Kenya
Sarah Roberts
RTI International, United States
Audience Q&A
Kawango Agot
Impact Research and Development Organization, Kenya
Sinead Delany-Moretlwe
Wits Reproductive Health and HIV Institute (Wits RHI), South Africa
Nanlesta Pilgrim
Population Council, United States
Sarah Roberts
RTI International, United States
Taking Gender Norms into Account to Increase HIV Service Use in the Community
Ann Gottert
Population Council, United States
An evaluation of a combination HIV prevention intervention that includes oral PrEP for adolescent girls and young women in South Africa and Tanzania
Sheila Harvey
The London School of Hygiene & Tropical Medicine, Tanzania
CHARISMA Pilot Results and Planned Randomized Controlled Trial
Elizabeth Montgomery
RTI International, United States
Audience Q&A
Jared Baeten
University of Washington, United States
Ann Gottert
Population Council, United States
Sheila Harvey
The London School of Hygiene & Tropical Medicine, Tanzania
Elizabeth Montgomery
RTI International, United States
Delivette Castor
USAID, United States
Sinead Delany-Moretlwe
Wits Reproductive Health and HIV Institute (Wits RHI), South Africa
Nanlesta Pilgrim
Population Council, United States
Sarah Roberts
RTI International, United States
Moving forward toward empowering women and ending HIV
Delivette Castor
USAID, United States
from HIV Research for Prevention 2018 on 22 October 2018 12:00-15:00
Satellite Session: HIV Vaccine Design and Development Partnerships in Africa: Showcasing African-led Basic HIV Prevention Science Research
Introduction and Welcome of Speakers
Pontiano Kaleebu
Medical Research Council/Uganda Virus Research Institute
Introduction and Welcome of Speakers
Peter Dukes
Africa Research Excellence Fund, The Gambia/Uganda/UK
VISTA model: Introduction
Jill Gilmour
International AIDS Vaccine Initiative
VISTA model: Transmission of multiple HIV-1 founder viruses with high level of recombination in MSM
Gladys Macharia
Kenya Medical Research Institute
VISTA model: Viral diversity, evolution and innate responses during acute HIV-1 infection and their association with disease pathogenesis
Amin Hassan
Kenya Medical Research Institute
MRC model South Africa: Developing Research Capacity & Addressing Transformation in RSA
Glenda Gray
Medical Research Council, South Africa
MRC model South Africa: Emerging findings in pox-protein HIV vaccine trials in South Africa
Fatima Laher
Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, South Africa
MRC model South Africa: Viral variants that initiate and drive the maturation of broadly neutralizing V1V2 antibodies
Jinal Bhiman
National Institute for Communicable Diseases, South Africa
EDCTP model: Introduction
Thomas Nyirenda
Eurpean & Developing Countries Clinical Trials Partnership
EDCTP model: Ex-vivo stimulation with HIV-1-specific antigens support the existence of NK-cell recall responses
Sabelle Jallow
Medical Research Council, The Gambia
EDCTP model: Enhanced Immunogenicity of oligomannose HIV-1env gp120 vaccines
Loveline Ngu
The Chantal Biya International Reference Center for Research on HIV/AIDS, Messa Yaounde, Cameroon
Q&A: Co-Chair
Pontiano Kaleebu
Medical Research Council/Uganda Virus Research Institute
Q&A: Co-Chair
Peter Dukes
Africa Research Excellence Fund, The Gambia/Uganda/UK
Q&A: Discussant
Sabelle Jallow
Medical Research Council, The Gambia
Q&A: Discussant
Glenda Gray
Medical Research Council, South Africa
Q&A: Discussant
Jinal Bhiman
National Institute for Communicable Diseases, South Africa
Q&A: Discussant
Jill Gilmour
International AIDS Vaccine Initiative
Achieving well-balanced partnerships: the AREF experience
Peter Dukes
Africa Research Excellence Fund, The Gambia/Uganda/UK
Launch of African AIDS Vaccine Virtual Network - Mission and Vision
Pontiano Kaleebu
Medical Research Council/Uganda Virus Research Institute
Panel Discussion: Co-Chair
Margaret McCluskey
US Agency for International Development
Panel Discussion: Co-Chair
William Snow
Global HIV Vaccine Enterprise
Panelist
Steven Wakefield
HIV Vaccine Trials Network
Panelist
Nelson Michael
U.S. Military HIV Research Program
Panelist
Nina Russell
Bill and Melinda Gates Foundation
Panelist
Claire Rekacewicz
Agence Nationale de Recherche sur le Sida et les hépatites virales, France
Panelist
Elioda Tumwesigye
Minister of Science and Technology, Uganda
Panelist
Mary Marovich
U.S. National Institutes of Health
Panelist
Thumbi Ndung’u
University of KwaZulu Natal, South Africa
Panelist
Deenan Pillay
Africa Health Research Institute, South Africa
from HIV Research for Prevention 2016 on 17 October 2016 08:30-12:30
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 9 of 9